Stoke Therapeutics counsel sells 627 shares

After the transaction, Jonathan Allan's reported direct position was 20,598 shares; the trading plan was adopted November 10, 2025.

Rhea-AI Filing Summary

Stoke Therapeutics, Inc.'s General Counsel & Corp Sec, Jonathan Allan, sold 627 shares of common stock on October 2, 2026, at $26.33 per share. The sale was made under a Rule 10b5-1 trading plan adopted November 10, 2025. Allan's reported direct holdings after the transaction were 20,598 shares.

Insider Trade Summary 10b5-1

Net Seller: 627 shares

Net Sell 1 txn

Insider Allan Jonathan

Role GENERAL COUNSEL & CORP SEC

Sold 627 shs ($17K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	627	$26.33	$17K

Holdings After Transaction: Common Stock — 20,598 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

Key Figures

Shares sold: 627 shares Sale price: $26.33 per share Direct holdings after transaction: 20,598 shares

3 metrics

Shares sold 627 shares October 2, 2026

Sale price $26.33 per share October 2, 2026

Direct holdings after transaction 20,598 shares After the October 2, 2026 sale

Key Terms

Rule 10b5-1 trading plan, non-derivative, direct ownership

3 terms

Rule 10b5-1 trading plan regulatory

"executed pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

non-derivative technical

"the Common Stock transaction was non-derivative"

direct ownership technical

"reported direct holdings after the transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many STOK shares did Jonathan Allan sell, and at what price?

Jonathan Allan sold 627 shares of STOK common stock on October 2, 2026, at $26.33 per share. The sale was made under a Rule 10b5-1 trading plan adopted November 10, 2025, and his reported direct holdings afterward were 20,598 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 05:38 PM Accepted by SEC EDGAR 10/02/2026 - 05:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2026		S(1)		627	D	$26.33	20,598	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

	/s/ Jonathan Allan	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)